Pushing PCR Further

A historic innovation

Since 1983, Roche has pioneered the advancement of PCR analysis, which is recognized as a gold standard in laboratory diagnostics. The cobas® Liat® PCR System replicates extracted DNA or RNA from patient samples to accurately identify infectious diseases. Using Roche PCR technology, laboratory-quality sensitivity and specificity are achieved across assays, significantly reducing the risk of false negative and false positive results.1

cobas-liat-historic-innovation-image

cobas® Strep A1

Strep A
Sensitivity: 97.7%

Specificity: 93.3%

cobas® Influenza A/B2

Influenza A
Sensitivity: 97.5%

Specificity: 97.9%

Influenza B
Sensitivity: 96.9%

Specificity: 97.9%

cobas® Influenza A/B & RSV3

Influenza A
Sensitivity: 97.5%

Specificity: 97.9%

Influenza B
Sensitivity: 96.9%

Specificity: 97.9%

cobas® Cdiff4

Cdiff
Sensitivity*: 93.5%

Specificity*: 96.4%

cobas® MRSA5

MRSA
Sensitivity: 94.5%

Specificity: 98.4%

SA
Sensitivity: 96.6%

Specificity: 96.3%

Quality without compromise

Patients deserve the best care possible—that means reliable results in a reasonably short amount of time. Current diagnostic options offer a trade-off between speed or accuracy, and since many diseases present similar symptoms at early stages, the need for a reliably accurate point-of-care testing solution is high.

Explore the pros and cons of current diagnostic options

Signs & symptoms

sign-symptopms-mobile-thumb-image

Pro

Quick diagnosis, based on knowledge and experience

Con

Could lead to incorrect antibiotic treatment

On-site rapid antigen test

on-site-rapid-tests-mobile-thumb-image

Pro

Fast results, easy to use

Con

Potentially less accurate, with uncertainty around negative results

Lab cultures

lab-cultures-mobile-thumb-image

Pro

Highly accurate and definitive

Con

Prolongs time for patient diagnosis

Based on Nobel Prize-winning PCR technology, you can be confident that the cobas® Liat® PCR System supports you in delivering the best patient care possible.
Explore the cobas® Liat® System

*Compared to culture and latex agglutination for Strep A typing; CLIA data.
**Compared to viral culture.
Compared to an FDA-cleared laboratory based multiplexed real-time reverse transcription PCR (RT-PCR) test; CLIA data.
††Compared to direct culture.
Compared to direct and enriched culture.
CI=confidence intervals.
cobas® Strep A, cobas® Influenza A/B and cobas® Influenza A/B & RSV are CE-IVD and FDA 510(k) cleared; CLIA waived. cobas® Cdiff and cobas® MRSA/SA are CE-IVD cleared.

References: 1. cobas® Strep A [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 2. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 3. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 4. cobas® Cdiff [package insert]. 5. cobas® MRSA/SA [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2017.